14:06:39 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande


ListaFirst North Stockholm
IndustriLäkemedel & Handel
Ziccum är ett svenskt läkemedelsbolag som utvecklar nya beredningar av biologiska läkemedel. Med bolagets patenterade teknologi LaminarPace utvecklas torra beredningsformer av produkter som i nuläget finns i vätskeform. Störst versamhet återfinns runtom Norden, samt utöver huvudverksamheten erbjuder bolaget diverse relaterade produkter. Bolagets huvudkontor ligger i Lund.


2023-01-27 Bokslutskommuniké 2022
2022-10-27 Kvartalsrapport 2022-Q3
2022-08-23 Kvartalsrapport 2022-Q2
2022-04-29 Ordinarie utdelning ZICC 0.00 SEK
2022-04-28 Årsstämma 2022
2022-04-28 Kvartalsrapport 2022-Q1
2022-02-17 Bokslutskommuniké 2021
2022-01-18 Extra Bolagsstämma 2022
2021-10-28 Kvartalsrapport 2021-Q3
2021-08-26 Kvartalsrapport 2021-Q2
2021-04-28 Ordinarie utdelning ZICC 0.00 SEK
2021-04-27 Årsstämma 2021
2021-04-23 Kvartalsrapport 2021-Q1
2021-02-11 Bokslutskommuniké 2020
2020-11-06 Kvartalsrapport 2020-Q3
2020-08-20 Kvartalsrapport 2020-Q2
2020-06-17 Ordinarie utdelning ZICC 0.00 SEK
2020-06-16 Årsstämma 2020
2020-04-17 Kvartalsrapport 2020-Q1
2020-02-13 Bokslutskommuniké 2019
2019-11-07 Kvartalsrapport 2019-Q3
2019-08-21 Kvartalsrapport 2019-Q2
2019-05-20 Årsstämma 2019
2019-05-10 Ordinarie utdelning ZICC 0.00 SEK
2019-05-09 Kvartalsrapport 2019-Q1


2022-06-22 08:30:00

Lund, June 22, 2022 —Ziccum AB (publ) (‘Ziccum’) has completed the installation of a new cell lab, on schedule, as part of its strategy of intensive technology development. The new cell lab increases the company’s capabilities in its own mRNA/LNP research and data generation. It will enable Ziccum to carry out in vitro studies on thermostable formulations of vaccines and biologics that do not require freezing or refrigeration to be stored or transported worldwide.

On April 26 Ziccum announced that it was in the process of installing a new cell lab to enable in vitro studies and increase its in-house capabilities in mRNA/LNP research. The target for completion was Q2 2022. That target has now been reached on schedule.

The new lab is part of Ziccum’s intensive strategy of stepwise technology development, running in parallel with a new streamlined portfolio of research projects focused on three targeted vaccine platforms.

mRNA/LNP (Lipid Nanoparticle) materials are seen by many as representing a new era in vaccinology, and were the crucial delivery vehicles that enabled both the Pfizer-BioNTech and Moderna COVID-19 vaccines. LaminarPace (LAPA), the company’s ambient drying system, achieved encouraging results with early dry formulations of LNP materials, which lead to the focus on the mRNA/LNP platform.

However, the new cell lab will not only strengthen Ziccum’s capabilities in mRNA/LNP. In the longer term it will offer increased opportunities to generate biological data on other platforms and substances.

Since September 2021 Ziccum’s technology development has accelerated significantly, driven by a highly structured Quality by Design approach that has led to important new features that have improved safety, cleanability and further reduced humidity of the LAPA system. The current LAPA, the fourth generation of the system, underwent an intensive Factory Acceptance Test, and a Site Acceptance Test on its installation at Ziccum’s facilities in June.

Director of Development Anna Lönn: “Structure, focus and scrupulous documentation are essential for successful industrial development. Since September this approach has accelerated development and delivered significant new enhancements and features. We are becoming more confident and mature, in parallel, in both our technology and project development. The new cell lab will enhance and accelerate our data generation and capabilities.”